Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Kaiser Permanente Survey Shows Seniors Embrace Internet To Manage Their Health
New data show that Medicare beneficiaries registered to use My Health Manager, Kaiser Permanente"s personal health record, are overwhelmingly satisfied with using the Internet to manage their health care online. Results from the recent Kaiser Permanente survey examining Web site usage and Medicare beneficiary satisfaction were presented today at the World Health Care Congress" 5th Annual Leadership Summit on Medicare in Washington, D.C.
generic viagra online
Dutch Ambulance Service First To Purchase ZOLL Integrated Automated Compression-Defibrillation System
ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, announced that the ambulance service, RAV Gooi en Vechtstreek in Hilversum, The Netherlands, is the first EMS organization to equip its ambulances with a revolutionary new system that allows rescuers to defibrillate a heart without the need to stop chest compressions.
News of the day
QIAGEN Launches Novel Product Enabling Non-Invasive Prenatal Diagnostics And Cancer Detection
QIAGEN announced the launch of a novel product for extraction of free circulating fragments of tumor- and fetal-derived nucleic acids as well as viral nucleic acids in human blood. Scientists consider these DNA and RNA fragments to have great potential for the highly sensitive and non-invasive diagnosis of a wide range of diseases, including congenital disorders, malignancies such as colon and lung cancer, and infections. The new QIAamp Circulating Nucleic Acid Kit is expected to significantly facilitate the corresponding biomarker research and the introduction of novel molecular tests in prenatal diagnostics which can replace risky, invasive procedures such as amniocentesis.
Cardiovascular

King Provides Additional Information On The REMOXY® NDA Resubmission Plan

King Pharmaceuticals, Inc. (NYSE: KG) announced additional information regarding the resubmission plan for the REMOXY® New Drug Application (NDA). The Company is not required by the Food and Drug Administration (FDA) to conduct clinical trials in order to provide additional safety or efficacy data in patients with moderate to severe chronic pain. However, as part of the resubmission plan, and in order to strengthen the NDA, King plans to conduct a likeability study and a pharmacokinetic trial in volunteers. The Company continues to anticipate the resubmission could occur mid-year 2010. About REMOXY® REMOXY, an investigational drug, is a unique, long-acting oxycodone formulation for moderate-to-severe chronic pain designed to reduce potential risks of unintended use. In mid-2008, an NDA for REMOXY was accepted by the FDA and was granted Priority Review. In December 2008, Pain Therapeutics received a Complete Response Letter from the FDA. Subsequent to the receipt of the Complete Response Letter, King assumed full control of all activities related to the development of REMOXY®. About King Pharmaceuticals, Inc. King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products that complement the Company"s focus in specialty-driven markets, particularly neuroscience, hospital care. King"s wholly-owned subsidiary, Alpharma, Inc., is also a leader in the development, registration, manufacturing and marketing of pharmaceutical products for food producing animals. Forward Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). King Pharmaceuticals, Inc. disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the resubmission of the NDA for REMOXY® and the timing and content of any such resubmission; the need to generate any information or conduct any study or trial in connection with the resubmission and the timing of any such study or trial. Such statements are based on management"s current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in preparation and resubmission of the NDA for REMOXY® and whether or when the NDA for REMOXY®,; the outcomes of any study or trial conducted in connection with the resubmission; and whether or when the NDA is approved by the FDA. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of King"s Annual Report on Form 10-K for the year ended December 31, 2008 and it"s Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, each of which is on file with the U.S. Securities and Exchange Commission. King Pharmaceuticals, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009